SRx Global Inc

SRx Global Inc (SRXH) Stock Analysis

$0.811

+0.011 (+1.39%)At close

Loading chart…
High
0.838
Open
0.808
VWAP
0.81
Volume
280.74K
Mkt Cap
—
Low
0.790
Amount
228.26K
EV/EBITDA, TTM
0.00

SRx Global Inc. is an artificial intelligence (AI)-driven platform focused on investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. The Company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors. Its portfolio includes EMJX and Halo pets. EMJX is a digital-asset treasury platform designed as a treasury operating system, applying models, artificial intelligence, and systematic risk controls to multi-asset digital treasury management. Halo pets is engaged in selling premium pet products for dogs and cats. Halo pets offer Dry Food, Freeze-Dried Raw, Wet Food, Toppers, Dental, Treats & Chews, and others. Its dry food includes Freeze-Dried Raw Beef Meal Bites 14 oz, Freeze-Dried Raw Turkey Meal Bites 14 oz, Holistic Vegan Plant-Based with Superfoods Recipe Adult Dry Dog Food, and others.

AI analysis of SRx Global Inc (SRXH)

Sell

Currently, SRx Health Solutions Inc (SRXH) is not a good buy. The stock has experienced a drastic year-to-date decline of 94.32% and a 5-day change of -19.69%, indicating severe downward momentum. The RSI is at a low 10.521, suggesting the stock is oversold but also reflecting weak demand. Additionally, the forward P/E ratio is 0, indicating a lack of expected earnings growth. The main risk is the significant debt burden reflected in the current ratio of 27.55, which, while indicating liquidity, shows a volatile financial position. Given these factors, it is advisable to avoid purchasing SRXH at this time.

Valuation Metrics

The current forward P/E ratio for SRx Global Inc (SRXH) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
Overvalued
0.00
Undervalued
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued
0.00
Undervalued
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
Overvalued
0.00
Undervalued
0.00

Alphio AI Price Scenarios for SRXH

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%SRXH

$0.65

Scenario price

B

Base

Base · 50%SRXH

$0.61

Scenario price

B

Bear

Bear · 25%SRXH

$0.58

Scenario price

Events Timeline

2026-08-04 (ET)

05:30:00

SRX Global Acquires Stake in Vistagen

2026-07-30 (ET)

14:30:00

SRX Global Acquires Shares in Jersey Mike's IPO

2026-07-09 (ET)

12:00:00

SRx Global Inc Trading Halted, News Pending

12:00:00

SRX Global Authorizes Repurchase of Up to 10M Shares

2026-07-08 (ET)

14:00:00

SRx Global Inc Trading Halted, News Pending

News

SRXH FAQ — answered by Alphio AI

SRx Global Inc. is an artificial intelligence (AI)-driven platform focused on investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. The Company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors. Its portfolio includes EMJX and Halo pets. EMJX is a digital-asset treasury platform designed as a treasury operating system, applying models, artificial intelligence, and systematic risk controls to multi-asset digital treasury management. Halo pets is engaged in selling premium pet products for dogs and cats. Halo pets offer Dry Food, Freeze-Dried Raw, Wet Food, Toppers, Dental, Treats & Chews, and others. Its dry food includes Freeze-Dried Raw Beef Meal Bites 14 oz, Freeze-Dried Raw Turkey Meal Bites 14 oz, Holistic Vegan Plant-Based with Superfoods Recipe Adult Dry Dog Food, and others. It operates in the Technology sector.

Currently, SRx Health Solutions Inc (SRXH) is not a good buy. The stock has experienced a drastic year-to-date decline of 94.32% and a 5-day change of -19.69%, indicating severe downward momentum. The RSI is at a low 10.521, suggesting the stock is oversold but also reflecting weak demand. Additionally, the forward P/E ratio is 0, indicating a lack of expected earnings growth. The main risk is the significant debt burden reflected in the current ratio of 27.55, which, while indicating liquidity, shows a volatile financial position. Given these factors, it is advisable to avoid purchasing SRXH at this time.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading